Lncrna Uca1 In Anti-Cancer Drug Resistance

Haohao Wang,Zhonghai Guan,Kuifeng He,Jiong Qian,Jiang Cao,Lisong Teng
DOI: https://doi.org/10.18632/oncotarget.18344
2017-01-01
Oncotarget
Abstract:The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
What problem does this paper attempt to address?